Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hernan Inojosa

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Fortschritte Der Neurologie-Psychiatrie|January 25, 2024
[Current and innovative Approaches to Multiple Sclerosis Therapy]Hernan Inojosa, Tjalf Ziemssen
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2020
How to reduce the delay of diagnosing secondary progression in multiple sclerosisHernan Inojosa, Tjalf Ziemssen
Autoimmunity Reviews|March 17, 2020
Clinical outcome measures in multiple sclerosis: A reviewHernan Inojosa, Dirk Schriefer, Tjalf Ziemssen
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 23, 2024
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practiceHernan Inojosa, Annika Kather, Katja Akgün, et al.
Frontiers in Neurology|February 8, 2021
Should We Use Clinical Tools to Identify Disease Progression?Hernan Inojosa, Undine Proschmann, Katja Akgün, et al.
Therapeutic Advances in Chronic Disease|January 24, 2022
The need for a strategic therapeutic approach: multiple sclerosis in checkHernan Inojosa, Undine Proschmann, Katja Akgün, et al.
Journal of Neurology|August 1, 2019
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definitionHernan Inojosa, Undine Proschmann, Katja Akgün, et al.
Multiple Sclerosis and Related Disorders|September 25, 2020
The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution studyHernan Inojosa, Benedict Rauser, Benjamin Ettle, et al.
Frontiers in Neurology|May 3, 2021
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple SclerosisUndine Proschmann, Hernan Inojosa, Katja Akgün, et al.
Fortschritte Der Neurologie-Psychiatrie|March 16, 2021
[MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis]Hernan Inojosa, Katja Akgün, Katrin Haacke, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Fortschritte Der Neurologie-Psychiatrie|January 25, 2024
[Current and innovative Approaches to Multiple Sclerosis Therapy]Hernan Inojosa, Tjalf Ziemssen
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2020
How to reduce the delay of diagnosing secondary progression in multiple sclerosisHernan Inojosa, Tjalf Ziemssen
Autoimmunity Reviews|March 17, 2020
Clinical outcome measures in multiple sclerosis: A reviewHernan Inojosa, Dirk Schriefer, Tjalf Ziemssen
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 23, 2024
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practiceHernan Inojosa, Annika Kather, Katja Akgün, et al.
Frontiers in Neurology|February 8, 2021
Should We Use Clinical Tools to Identify Disease Progression?Hernan Inojosa, Undine Proschmann, Katja Akgün, et al.
Therapeutic Advances in Chronic Disease|January 24, 2022
The need for a strategic therapeutic approach: multiple sclerosis in checkHernan Inojosa, Undine Proschmann, Katja Akgün, et al.
Journal of Neurology|August 1, 2019
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definitionHernan Inojosa, Undine Proschmann, Katja Akgün, et al.
Multiple Sclerosis and Related Disorders|September 25, 2020
The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution studyHernan Inojosa, Benedict Rauser, Benjamin Ettle, et al.
Frontiers in Neurology|May 3, 2021
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple SclerosisUndine Proschmann, Hernan Inojosa, Katja Akgün, et al.
Fortschritte Der Neurologie-Psychiatrie|March 16, 2021
[MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis]Hernan Inojosa, Katja Akgün, Katrin Haacke, et al.
Pageof 4